



VolitionRx MicroCapClub Invitational

8 January 2014



Public Company Profile: VNRX



- Market capitalization: ~22 million
- Shares outstanding: 11.19 million
- Insider ownership: 60%
- Cash: ~\$975,000 + outstanding grants
- Debt: \$0
- Burn rate: \$220,000/month

Need for Better CRC Diagnosis

- Current CRC diagnostics:
 - Colonoscopy
 - FIT/FOBT
- Blood better:
 - FIT compliance 30-60%
 - PSA compliance at least 80%
 - 95% of people would rather take a blood test than a colonoscopy or fecal test




Nucleosomics® – How It Works



- The DNA in every cell is wound around protein complexes in a “beads on a string” structure.
- Each individual “bead” is called a nucleosome.
- When a cell dies, the body breaks the DNA string up into individual nucleosomes which are released into the blood to be naturally “recycled”.
- Cancer is characterized by uncontrolled and rapid cell turnover. As the body can’t recycle such large amounts of cell “debris”, the nucleosome level rises in a cancer patient’s blood.


Nucleosomics® – How It Works



- More than just a biomarker – a new army of biomarkers
- VNRX holds IP covering:
 - DNA modification
 - Histone modification
 - Histone variants
 - Adducts
 - Total nucleosomes


Volition's NuQ[®] Suite of Tests

- Two types of tests:
 - Screening tests e.g. colonoscopy
 - Diagnostic tests e.g. scan; biopsy
- Multiple NuQ assays
- “Panel” of assays = cancer test
- Patient has 1 small blood draw



Results to Date

- Results presented at Clinical Genomics and Informatics Europe, Dec 2013
 - Preliminary findings from CHU Dinant Godinne | UCL Namur Hospital in Belgium.
 - Colorectal cancer two-assay panel test
 - **85% detection rates at 85% specificity**
 - **50% of precancerous polyps detected**
- Results presented at CNAPS conference, Nov 2013:
 - Colorectal cancer single-assay test:
 - **75% of cancers detected, 70% specificity (90 patients, one single assay); data reconfirmed on further 113 patients**
- Nov 2012: Preliminary results:
 - Colon: 76% of cancers detected at 90% specificity
 - Breast: 96% of cancers detected at 90% specificity
 - Lung: 100% of cancers at 79% specificity



Clinical Trials

- First 1,000 or approx 16,000 samples from Denmark have been delivered; analysis started end 2013

Cancer Type	Institution	Sample Collection	Start Date (approx.)	No. of Patients	Other Information
Colorectal	Hvidovre Hospital, Denmark	Retrospective: took place 2010-2012	Analysis to start in 2013; end 2014	4,800	Volition will analyze samples from a diagnostic population of healthy individuals, patients with colorectal cancer, other malignancies, polyps or adenomas, and benign bowel diseases, all of whom have undergone a colonoscopy; with full access to all national registries and databases (electronic audit).
Colorectal	Hvidovre Hospital, Denmark	Prospective: scheduled for 2014 start	Analysis to start in 2014; end 2015	11,000	Volition will co-sponsor a population screening study with a top-10 global diagnostics company and the University of Copenhagen/Hvidovre Hospital. All patients will also have a fecal occult blood test and a colonoscopy and we have full access to their medical history through electronic audit.
Colorectal	UCL Dinant Godinne UCL Namur	Prospective: started 2012 and is ongoing	Analysis of first samples underway	250	Volition is currently analyzing blood samples from patients with a potential digestive pathology (including a mixture of suspected colorectal cancer, polyp, inflammatory bowel disease, Crohn's disease and colitis). Patients with negative colonoscopy for IBD, polyp or cancer will form an age-matched healthy control cohort.
20 most prevalent cancers	Bonn University, Germany	Prospective	Following collection	2,000	Volition will analyze blood samples from a combination of: healthy individuals; patients with cancers (age- and gender-matched) including twenty of the most prevalent major organ and hematological cancers; and patients with other conditions including organ-related benign diseases, metabolic diseases such as renal failure and autoimmune disease, acute diseases such as sepsis, inflammation, trauma and stroke, and chronic degenerative diseases

Product Development: Clinical Kits

- ELISA platform very stable: >30 years old
- Nucleosomics is at the cutting edge of science
- NuQ® tests can be adapted onto four existing ELISA diagnostic platforms




*Volition's manual ELISA format
(same as RUO kits)*



*The Abbott Architect – a machine of
a type which could be used for
Volition's tests*



*A machine similar to that which
could be used to run Volition's point-
of-care tests*



*An example of the type of format
which Volition could use for its
disposable tests*

Investment Highlights

- Blood-based tests are the future of cancer diagnostics – higher compliance rates than current tests
- VNRX is developing diagnostic and screening blood tests for a range of cancers, beginning with CRC
- Promising early results, shortly to begin 4,800 patient retrospective trial and 11,000 individual screening trial for CRC
- Volition's Nucleosomics® tests are based on simple but cutting-edge science and are inexpensive to produce but with high potential selling cost with little direct competition.
- Volition has strong patent protection from applications in USA and Europe, for all key technologies.



VolitionRX

OTCBB: VNRX



This presentation is available for download
in the Investor Relations section of
VolitionRx's website at:

<http://volitionrx.com/investor-downloads/category/3-presentations.html>



Contact

Centre Technologique
Rue du Séminaire, 20A
BE-5000 Namur
Belgium
www.volitionrx.com

CEO: Cameron
Reynolds
c.reynolds@volitionrx.com

CSO: Jake Micallef
j.micallef@volitionrx.com

Updated
January
2014